1. Following a SARS-CoV-2 (COVID-19) infection, patients who received the Moderna mRNA-1273 vaccine were less likely to develop anti-nucleocapsid antibodies ...
1. Patients reported a high burden of persistent symptoms more than six weeks after recovery from coronavirus disease 2019 (COVID-19). ...
1. An interval of 44-45 weeks between the first and second dose resulted in a four-fold increase in median antibody ...
Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group ...
1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 ...
1. A similar proportion of patients died within 28 days of randomization in both groups (high-titre convalescent plasma vs. usual ...
1. In this cross-sectional study of Japanese patients with cancer and health care workers, the seroprevalence of SARS-CoV-2 antibodies did ...
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their ...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. ...
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one ...
